slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 41,881-41,910
Pages 2,019
Rows per page 30
Component
41,881-41,910 of 60,568
06
The table uses a standard pharmaceutical pipeline layout with clinical and preclinical segments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem & Complication1 hit
15
The slide uses a table structure to contrast clinical outcomes across three key value pillars: response rates, tolerability, and outpatient feasibility.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
17
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
19
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
21
The slide uses a red dashed box to highlight the core clinical data rows for comparison.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
23
The table uses a red dashed box to highlight the core clinical data rows.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
24
The slide highlights specific safety data points for a competitor product to establish a benchmark.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
25
The slide uses a structured table format to map clinical trial progress against specific disease indications.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
34
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
35
The chart is a conceptual visualization of 100% of patients achieving 4 months mPFS.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
26
The slide highlights specific safety metrics for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
27
Includes a footer citing FDA approval precedents for patient population sizes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The slide uses a bubble chart to map mPFS against patient treatment history and a table to detail clinical outcomes across lines of therapy.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
The chart visualizes a single data point (4 months mPFS at 100% pre-treated status) while the table provides detailed clinical trial outcomes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
49
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
Includes financial strength ratings from AM Best and S&P Global.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations Beat · Setup1 hit
09
The slide uses a side-by-side comparison structure for two distinct time periods.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations Beat · Financial Performance OverviewLoop · Cost Of Inaction1 hit
17
The table distinguishes between IFRS (audited) and U.S. GAAP (unaudited) reporting standards.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations 1 hit
18
The table includes annual data from 2017-2022 under IFRS and U.S. GAAP, plus quarterly comparisons for 2022 and 2023.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations 1 hit
10
Includes a footnote regarding pro-forma adjustments and rounding.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · Zoom In1 hit
12
The table includes specific line items for revenue, margins, operating expenses, and cash position.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · Zoom In1 hit
14
The slide includes detailed footnotes explaining adjustments to the cash burn figures for specific quarters.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations Beat · Key Performance Indicators Overview1 hit
21
Includes pro forma adjustments for exited businesses and geographies.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
22
Pro forma figures exclude exited businesses and geographies.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
23
Trended 8 quarter view at ir.invitae.comInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
24
Trended 8 quarter view at ir.invitae.comInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
25
The table details specific line items like impairment, restructuring costs, and stock-based compensation adjustments.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
26
Trended 8 quarter view at ir.invitae.comInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit
27
The table reconciles net cash flow changes to cash burn, including adjustments for investments and debt issuance.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations 1 hit